Barclays’s Singular Genomics Systems, Inc. Common Stock OMIC Stock Holding History

Barclays’s Portfolio OMIC Stock Details OMIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-409	Closed	-$7.95K	–	5697
2024 Q4	$7.95K	Hold	409	–	–	﹤0.01%	5020
2024 Q3	$6.41K	Hold	409	–	–	﹤0.01%	5008
2024 Q2	$3.46K	Hold	409	–	–	﹤0.01%	4601
2024 Q1	$6.32K	Hold	409	–	–	﹤0.01%	4850
2023 Q4	$5.65K	Hold	409	–	–	﹤0.01%	5024
2023 Q3	$4.68K	Hold	409	–	–	﹤0.01%	4392
2023 Q2	$10.2K	Sell	409 -960	-70%	-$28.1K	﹤0.01%	4218
2023 Q1	$49.7K	Buy	1,369 +454	+50%	+$27.8K	﹤0.01%	4446
2022 Q4	$55.2K	Buy	915 +427	+88%	+$28.6K	﹤0.01%	4514
2022 Q3	$37K	Sell	488 -15	-3%	-$1.57K	﹤0.01%	3871
2022 Q2	$58K	Sell	503 -25	-5%	-$2.93K	﹤0.01%	3983
2022 Q1	$100K	Buy	+528	New	+$122K	﹤0.01%	3777

Barclays's OMIC Position: Q1 2025 in Review

Barclays sold out of Singular Genomics Systems, Inc. Common Stock (OMIC) in Q1 2025, closing a stake of 409 shares — an estimated $7.95K sold.

Barclays first reported a position in OMIC in Q1 2022 and held it in 12 quarters. The position peaked at $100K in Q1 2022. 0 funds tracked by Wall St. Rank hold OMIC as of Q1 2025.

Barclays reported no remaining Singular Genomics Systems, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
Barclays sold 409 Singular Genomics Systems, Inc. Common Stock shares in Q1 2025, an estimated $7.95K.
Barclays first reported a position in Singular Genomics Systems, Inc. Common Stock in Q1 2022 and held it in 12 quarters.
Barclays's Singular Genomics Systems, Inc. Common Stock position peaked at $100K in Q1 2022.
0 funds tracked by Wall St. Rank held Singular Genomics Systems, Inc. Common Stock as of Q1 2025.

Based on Barclays's 13F filing for Q1 2025, filed 15 May 2025.